Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2019

View Archived Issues

Arcturus receives additional support from CF Foundation to develop mRNA therapies to treat CF

AC Immune initiates phase Ib/IIa study of ACI-35.030 vaccine for the treatment of AD

VHIO and BST co-launch clinical trial of ViroTCell

UBL4A acts as an authophagy inhibitor and tumor suppressor in pancreatic ductal adenocarcinoma

Vacuolar protein sorting 35 is a regulator of tau phosphorylation and neuropathology

Novel VEGFR-2 inhibitors show significant antiproliferative activity in preclinical models

Oncoceutics reports phase I data for ONC-201

Better blood diagnostics with a different Holmes

A spoonful of sugar helps immunity calm down

MolMed describes chimeric antigen receptors targeting CD44

ALDH1 antigen-pulsed dendritic cells created at the University of Michigan

AC Immune patents agents targeting misfolded human TAR DNA-binding protein 43

Sosei Heptares and Takeda enter into new strategic partnership

California Institute of Technology, University of Tennessee present DPAGT1 inhibitors

Idorsia Pharmaceuticals identifies C5aR antagonists

Cancer research leads to pregnancy insights

FDA approves Turalio as first therapy for rare and debilitating joint tumor

Phase III IMvigor130 study of Tecentriq meets coprimary endpoint

Trifunctional natural killer cell engagers targeting tumor antigens control tumor growth in vivo

Pivotal phase III RESET study of rivipansel does not meet primary nor key secondary endpoints

Positive phase II data presented for dry powder inhaler formulation of ensifentrine

Analysis of phase III study of masitinib in melanoma carrying a mutation in JM domain of c-Kit

Telix Pharmaceuticals and DKFZ enter into collaboration agreement for image-guided prostate surgery

Poxel initiates PK/PD trial as part of its phase IIa clinical program for PXL-770